{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:37:26Z","timestamp":1780630646933,"version":"3.54.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An increasing number of patients are presenting to allergists with concerns about mast cell activation syndrome (MCAS), often in the context of persistent, unexplained, multisystem symptoms. This review aims provide a practical, stepwise approach to the diagnosis and management of MCAS, based on the consensus criteria established by the European Competence Network on Mastocytosis\u2014American Initiative on Mast Cell Diseases, an international consortium of leading experts in mast cell disorders endorsed by major scientific organizations. The first step is to evaluate whether the clinical presentation is consistent with MCAS, recognizing that the prototypical presentation is idiopathic anaphylaxis. Symptoms should be severe, episodic, typical of mast cell activation, and involve at least two organ systems. The next step is to exclude secondary causes of mast cell activation, particularly cofactor-dependent food allergy and nonsteroidal anti-inflammatory drug hypersensitivity. Objective evidence of mast cell activation must then be obtained, preferably by identifying an acute increase in serum tryptase (on a sample drawn within four hours of an episode) compared to baseline. Alternatively, urinary metabolites of mast cell mediators can be assessed by comparing baseline values with those obtained 3\u20136\u00a0h post-event. Importantly,elevated baseline values in serum tryptase or urinary metabolites are not diagnostic of MCAS, nor do normal values exclude the diagnosis. In patients with idiopathic anaphylaxis, evaluation for a clonal mast cell disorder is recommended. This includes measuring baseline serum tryptase, testing for the KIT p.D816V mutation in peripheral blood (using high-sensitivity assays, if available), and calculating a mast cell clonality prediction score. A bone marrow biopsy should be considered for those with a high probability of mast cell clonality. Management includes instructing patients to treat acute episodes with an epinephrine auto-injector, particularly when anaphylaxis criteria are met. For patients with recurrent episodes, prophylactic therapy may be initiated, starting with H1-antihistamines and stepping-up as needed. While most patients have a favourable clinical course, some may require multiple medications to prevent or attenuate episodes. Future research should focus on validating and refining diagnostic and therapeutic strategies. In clinical practice, expanding access to key diagnostic tools\u2014such as urinary mediator assays, sensitive KIT mutation testing, and tryptase genotyping\u2014would facilitate and improve care of those patients.<\/jats:p>","DOI":"10.1186\/s13223-025-00998-9","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:17:16Z","timestamp":1763734636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach"],"prefix":"10.1186","volume":"21","author":[{"given":"Erika","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"6","key":"998_CR1","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","volume":"126","author":"C Akin","year":"2010","unstructured":"Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099-104 e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"998_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000328760","volume":"157","author":"P Valent","year":"2012","unstructured":"Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215\u201325.","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"998_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","volume":"10","author":"P Valent","year":"2022","unstructured":"Valent P, Hartmann K, Bonadonna P, Gulen T, Brockow K, Alvarez-Twose I, et al. Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM consortium. J Allergy Clin Immunol Pract. 2022;10(8):1941\u201350.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"998_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","volume":"7","author":"P Valent","year":"2019","unstructured":"Valent P, Akin C. Doctor, i think i am suffering from MCAS: differential diagnosis and separating facts from fiction. J Allergy Clin Immunol Pract. 2019;7(4):1109\u201314.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"998_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000501079","volume":"180","author":"P Valent","year":"2019","unstructured":"Valent P, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180(1):44\u201351.","journal-title":"Int Arch Allergy Immunol"},{"issue":"3 Suppl","key":"998_CR6","doi-asserted-by":"publisher","first-page":"S19S","DOI":"10.1111\/1523-1747.ep12468945","volume":"96","author":"LJ Roberts 2nd","year":"1991","unstructured":"Roberts LJ 2nd, Oates JA. Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol. 1991;96(3 Suppl):S19S \u2013 S24.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"998_CR7","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","volume":"9","author":"T Gulen","year":"2021","unstructured":"Gulen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, et al. Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review. J Allergy Clin Immunol Pract. 2021;9(11):3918\u201328.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"998_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","volume":"144","author":"CR Weiler","year":"2019","unstructured":"Weiler CR, Austen KF, Akin C, Barkoff MS, Bernstein JA, Bonadonna P, et al. AAAAI mast cell disorders committee work group report: mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019;144(4):883\u201396.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"998_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/dx-2020-0005","volume":"8","author":"LB Afrin","year":"2021","unstructured":"Afrin LB, Ackerley MB, Bluestein LS, Brewer JH, Brook JB, Buchanan AD, et al. Diagnosis of mast cell activation syndrome: a global \u201cconsensus-2.\u201d Diagnosis (Berl). 2021;8(2):137\u201352.","journal-title":"Diagnosis (Berl)"},{"issue":"1","key":"998_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2024.09.006","volume":"155","author":"BD Solomon","year":"2025","unstructured":"Solomon BD, Khatri P. Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria. J Allergy Clin Immunol. 2025;155(1):213\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"998_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jaci.2024.05.025","volume":"154","author":"M Castells","year":"2024","unstructured":"Castells M, Giannetti MP, Hamilton MJ, Novak P, Pozdnyakova O, Nicoloro-SantaBarbara J, et al. Mast cell activation syndrome: current understanding and research needs. J Allergy Clin Immunol. 2024;154(2):255\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"998_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jaip.2024.01.013","volume":"12","author":"C Akin","year":"2024","unstructured":"Akin C. Dilemma of mast cell activation syndrome: overdiagnosed or underdiagnosed? J Allergy Clin Immunol Pract. 2024;12(3):762\u20133.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"998_CR13","doi-asserted-by":"publisher","first-page":"1513199","DOI":"10.3389\/fneur.2025.1513199","volume":"16","author":"L Yao","year":"2025","unstructured":"Yao L, Subramaniam K, Raja KM, Arunachalam A, Tran A, Pandey T, et al. Association of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patients; prevalence, overlap and response to therapy depends on the definition. Front Neurol. 2025;16:1513199.","journal-title":"Front Neurol"},{"issue":"17","key":"998_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021002","volume":"10","author":"R Kohno","year":"2021","unstructured":"Kohno R, Cannom DS, Olshansky B, Xi SC, Krishnappa D, Adkisson WO, et al. Mast cell activation disorder and postural orthostatic tachycardia syndrome: a clinical association. J Am Heart Assoc. 2021;10(17):e021002.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"998_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12016-019-08755-8","volume":"58","author":"AH Kucharik","year":"2020","unstructured":"Kucharik AH, Chang C. The relationship between Hypermobile Ehlers-Danlos syndrome (hEDS), Postural Orthostatic Tachycardia syndrome (POTS), and Mast Cell Activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273\u201397.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"998_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.anai.2020.08.015","volume":"125","author":"P Vadas","year":"2020","unstructured":"Vadas P, Guzman J, McGillis L, Mittal N, Walsh S. Cosegregation of postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome. Ann Allergy Asthma Immunol. 2020;125(6):719\u201320.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"998_CR17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/all.15188","volume":"77","author":"JB Wechsler","year":"2022","unstructured":"Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy. 2022;77(4):1288\u201391.","journal-title":"Allergy"},{"issue":"5","key":"998_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.anai.2024.08.021","volume":"133","author":"MR Elliott","year":"2024","unstructured":"Elliott MR, O\u2019Connor AE, Marshall GD. Inflammatory pathways in patients with post-acute sequelae of COVID-19: the role of the clinical immunologist. Ann Allergy Asthma Immunol. 2024;133(5):507\u201315.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"998_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jaip.2023.11.041","volume":"12","author":"T Zaghmout","year":"2024","unstructured":"Zaghmout T, Maclachlan L, Bedi N, Gulen T. Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders. J Allergy Clin Immunol Pract. 2024;12(3):753\u201361.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"998_CR20","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","volume":"10","author":"P Valent","year":"2022","unstructured":"Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, et al. Personalized management strategies in mast cell disorders: ECNM-AIM user\u2019s guide for daily clinical practice. J Allergy Clin Immunol Pract. 2022;10(8):1999\u20132012s.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"998_CR21","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1016\/j.jaip.2021.04.062","volume":"9","author":"LP De Puysseleyr","year":"2021","unstructured":"De Puysseleyr LP, Ebo DG, Elst J, Faber MA, Poorten MV, Van Gasse AL, et al. Diagnosis of primary mast cell disorders in anaphylaxis: value of KIT D816V in peripheral blood. J Allergy Clin Immunol Pract. 2021;9(8):3176\u201387.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"998_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","volume":"7","author":"P Valent","year":"2019","unstructured":"Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125\u201333.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"998_CR23","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jaip.2019.10.048","volume":"8","author":"MP Giannetti","year":"2020","unstructured":"Giannetti MP, Akin C, Castells M. Idiopathic anaphylaxis: a form of mast cell activation syndrome. J Allergy Clin Immunol Pract. 2020;8(4):1196\u2013201.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"998_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaip.2021.11.031","volume":"10","author":"C Slapnicar","year":"2022","unstructured":"Slapnicar C, Lebovic G, McParland A, Dozois M, Vadas P. Reproducibility of symptom sequences across episodes of recurrent anaphylaxis. J Allergy Clin Immunol Pract. 2022;10(2):534\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"998_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1081-1206(10)61367-1","volume":"97","author":"LM Webb","year":"2006","unstructured":"Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol. 2006;97(1):39\u201343.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"998_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jaip.2015.09.021","volume":"4","author":"P Vadas","year":"2016","unstructured":"Vadas P, Sinilaite A, Chaim M. Cholinergic urticaria with anaphylaxis: an underrecognized clinical entity. J Allergy Clin Immunol Pract. 2016;4(2):284\u201391.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"998_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.anai.2019.08.024","volume":"124","author":"MC Carter","year":"2020","unstructured":"Carter MC, Akin C, Castells MC, Scott EP, Lieberman P. Idiopathic anaphylaxis yardstick: practical recommendations for clinical practice. Ann Allergy Asthma Immunol. 2020;124(1):16\u201327.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"998_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jaci.2014.05.013","volume":"134","author":"HA Sampson","year":"2014","unstructured":"Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, et al. Food allergy: a practice parameter update-2014. J Allergy Clin Immunol. 2014;134(5):1016\u201325.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"998_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.anai.2023.03.017","volume":"130","author":"J Bartra","year":"2023","unstructured":"Bartra J, Turner PJ, Munoz-Cano RM. Cofactors in food anaphylaxis in adults. Ann Allergy Asthma Immunol. 2023;130(6):733\u201340.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"998_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jaip.2018.06.018","volume":"7","author":"MJ Christensen","year":"2019","unstructured":"Christensen MJ, Eller E, Mortz CG, Brockow K, Bindslev-Jensen C. Wheat-dependent cofactor-augmented anaphylaxis: a prospective study of exercise, aspirin, and alcohol efficacy as cofactors. J Allergy Clin Immunol Pract. 2019;7(1):114\u201321.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"998_CR31","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2014.08.024","volume":"135","author":"K Brockow","year":"2015","unstructured":"Brockow K, Kneissl D, Valentini L, Zelger O, Grosber M, Kugler C, et al. Using a gluten oral food challenge protocol to improve diagnosis of wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol. 2015;135(4):977\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"998_CR32","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.jaip.2024.05.037","volume":"12","author":"N Oztop","year":"2024","unstructured":"Oztop N, Vitus MV, Faihs V, Kugler C, Biedermann T, Brockow K. Test panel of hidden allergens for \u201cidiopathic anaphylaxis\u201d reveals wheat allergy dependent on augmentation factors as common final diagnosis. J Allergy Clin Immunol Pract. 2024;12(9):2337\u201346.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"998_CR33","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1111\/all.14797","volume":"76","author":"IJ Skypala","year":"2021","unstructured":"Skypala IJ, Bartra J, Ebo DG, Antje Faber M, Fernandez-Rivas M, Gomez F, et al. The diagnosis and management of allergic reactions in patients sensitized to non-specific lipid transfer proteins. Allergy. 2021;76(8):2433\u201346.","journal-title":"Allergy"},{"key":"998_CR34","unstructured":"Government of Canada. Ticks in Canada 2024 [Accessed: August 24, 2025]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/ticks-tick-borne-diseases\/ticks.html."},{"issue":"3","key":"998_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/all.14032","volume":"75","author":"I Dona","year":"2020","unstructured":"Dona I, Perez-Sanchez N, Eguiluz-Gracia I, Munoz-Cano R, Bartra J, Torres MJ, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020;75(3):561\u201375.","journal-title":"Allergy"},{"issue":"3","key":"998_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","volume":"149","author":"A Mateja","year":"2022","unstructured":"Mateja A, Wang Q, Chovanec J, Kim J, Wilson KJ, Schwartz LB, et al. Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. J Allergy Clin Immunol. 2022;149(3):1010\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"998_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","volume":"132","author":"DBK Golden","year":"2024","unstructured":"Golden DBK, Wang J, Waserman S, Akin C, Campbell RL, Ellis AK, et al. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124\u201376.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"998_CR38","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.jaip.2022.03.008","volume":"10","author":"JH Butterfield","year":"2022","unstructured":"Butterfield JH. Nontryptase urinary and hematologic biomarkers of mast cell expansion and mast cell activation: status 2022. J Allergy Clin Immunol Pract. 2022;10(8):1974\u201384.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"998_CR39","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","volume":"8","author":"J Butterfield","year":"2020","unstructured":"Butterfield J, Weiler CR. The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome. J Allergy Clin Immunol Pract. 2020;8(8):2533\u201341.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"998_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jaip.2019.08.022","volume":"8","author":"CR Weiler","year":"2020","unstructured":"Weiler CR. Mast cell activation syndrome: tools for diagnosis and differential diagnosis. J Allergy Clin Immunol Pract. 2020;8(2):498\u2013506.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"998_CR41","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.jaip.2023.02.017","volume":"11","author":"JH Butterfield","year":"2023","unstructured":"Butterfield JH. Increased excretion of mast cell mediator metabolites during mast cell activation syndrome. J Allergy Clin Immunol Pract. 2023;11(8):2542\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"998_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","volume":"39","author":"E Ono","year":"2009","unstructured":"Ono E, Taniguchi M, Mita H, Fukutomi Y, Higashi N, Miyazaki E, et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy. 2009;39(1):72\u201380.","journal-title":"Clin Exp Allergy"},{"key":"998_CR43","unstructured":"Mayo Clinic Laboratories. N-methylhistamine, Random, Urine [Accessed. Available from: https:\/\/www.mayocliniclabs.com\/test-catalog\/overview\/604981."},{"key":"998_CR44","unstructured":"Mayo Clinic Laboratories. 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha, Random, Urine [Accessed: August 24, 2025]. Available from: https:\/\/www.mayocliniclabs.com\/test-catalog\/overview\/606356."},{"key":"998_CR45","unstructured":"Mayo Clinic Laboratories. Leukotriene E4, Random, Urine [Accessed: August 24, 2025]. Available from: https:\/\/www.mayocliniclabs.com\/test-catalog\/overview\/606354."},{"issue":"6","key":"998_CR46","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","volume":"125","author":"I Alvarez-Twose","year":"2010","unstructured":"Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, Matito A, Esteban-Lopez MI, Vega A, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6):1269\u201378.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"998_CR47","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","volume":"110","author":"C Akin","year":"2007","unstructured":"Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis. Blood. 2007;110(7):2331\u20133.","journal-title":"Blood"},{"issue":"2","key":"998_CR48","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000096442","volume":"142","author":"K Sonneck","year":"2007","unstructured":"Sonneck K, Florian S, Mullauer L, Wimazal F, Fodinger M, Sperr WR, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2007;142(2):158\u201364.","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"998_CR49","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.jaip.2023.05.012","volume":"11","author":"D Gonzalez de Olano","year":"2023","unstructured":"Gonzalez de Olano D, Cain WV, Bernstein JA, Akin C. Disease spectrum of anaphylaxis disorders. J Allergy Clin Immunol Pract. 2023;11(7):1989\u201396.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"998_CR50","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","volume":"141","author":"MC Carter","year":"2018","unstructured":"Carter MC, Desai A, Komarow HD, Bai Y, Clayton ST, Clark AS, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin Immunol. 2018;141(1):180\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"998_CR51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000329856","volume":"157","author":"I Alvarez-Twose","year":"2012","unstructured":"Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, Matito A, Jara-Acevedo M, Teodosio C, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2012;157(3):275\u201380.","journal-title":"Int Arch Allergy Immunol"},{"issue":"9","key":"998_CR52","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cea.12369","volume":"44","author":"T Gulen","year":"2014","unstructured":"Gulen T, Hagglund H, Sander B, Dahlen B, Nilsson G. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy. 2014;44(9):1179\u201387.","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"998_CR53","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jaip.2022.11.042","volume":"11","author":"TA Rama","year":"2023","unstructured":"Rama TA, Torrado I, Henriques AF, Sanchez-Munoz L, Jara-Acevedo M, Navarro-Navarro P, et al. Mast cell activation syndromes: comparison between two scoring models to predict for mast cell clonality. J Allergy Clin Immunol Pract. 2023;11(3):908\u201319.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"998_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/ACI.0000000000000813","volume":"22","author":"MP O\u2019Connell","year":"2022","unstructured":"O\u2019Connell MP, Lyons JJ. Resolving the genetics of human tryptases: implications for health, disease, and clinical use as a biomarker. Curr Opin Allergy Clin Immunol. 2022;22(2):143\u201352.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"998_CR55","doi-asserted-by":"crossref","unstructured":"Akin C, Butterfield JH, Castells M, Lyons JJ. Management of indolent mastocytosis and mast cell activation syndrome: A clinical yardstick. Ann Allergy Asthma Immunol. 2025.","DOI":"10.1016\/j.anai.2025.06.032"},{"key":"998_CR56","unstructured":"ARUP Laboratories. TPSAB1 Copy Number Analysis by ddPCR [Accessed: August 24, 2025]. Available from: https:\/\/ltd.aruplab.com\/Tests\/Pub\/3017399."},{"key":"998_CR57","unstructured":"Gene by Gene. Tryptase Copy Number Variation Testing [Accessed: August 24, 2025]. Available from: https:\/\/www.genebygene.com\/service\/tryptase."},{"issue":"3","key":"998_CR58","first-page":"282","volume":"23","author":"AE Sirvent","year":"2010","unstructured":"Sirvent AE, Gonzalez C, Enriquez R, Fernandez J, Millan I, Barber X, et al. Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease. J Nephrol. 2010;23(3):282\u201390.","journal-title":"J Nephrol"},{"issue":"4","key":"998_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11882-024-01136-y","volume":"24","author":"H Shin","year":"2024","unstructured":"Shin H, Lyons JJ. Alpha-tryptase as a risk-modifying factor for mast cell-mediated reactions. Curr Allergy Asthma Rep. 2024;24(4):199\u2013209.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"8","key":"998_CR60","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.jaip.2022.03.001","volume":"10","author":"G Hoermann","year":"2022","unstructured":"Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B, et al. Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US cooperative group. J Allergy Clin Immunol Pract. 2022;10(8):1953\u201363.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"998_CR61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","volume":"64","author":"G Greiner","year":"2018","unstructured":"Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitterbauer-Hohendanner G, et al. Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis. Clin Chem. 2018;64(3):547\u201355.","journal-title":"Clin Chem"},{"issue":"2","key":"998_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","volume":"13","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13(2):180\u20138.","journal-title":"J Mol Diagn"},{"key":"998_CR63","unstructured":"ARUP Laboratories. KIT (D816V) Mutation by ddPCR, Quantitative [Accessed: August 24, 2025]. Available from: https:\/\/ltd.aruplab.com\/Tests\/Pub\/3002956."},{"issue":"5","key":"998_CR64","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jaci.2022.04.025","volume":"150","author":"MP Giannetti","year":"2022","unstructured":"Giannetti MP, Godwin G, Weller E, Butterfield JH, Castells M. Differential mast cell mediators in systemic mastocytosis and hereditary alpha-tryptasemia. J Allergy Clin Immunol. 2022;150(5):1225\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"998_CR65","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1016\/j.jaip.2024.08.044","volume":"12","author":"P Valent","year":"2024","unstructured":"Valent P, Hartmann K, Hoermann G, Reiter A, Alvarez-Twose I, Brockow K, et al. Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM. J Allergy Clin Immunol Pract. 2024;12(12):3250\u201360.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"998_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.anai.2016.10.031","volume":"118","author":"DB Golden","year":"2017","unstructured":"Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: a practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28\u201354.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"998_CR67","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaip.2017.03.019","volume":"5","author":"B Vos","year":"2017","unstructured":"Vos B, van Anrooij B, van Doormaal JJ, Dubois AEJ, Oude Elberink JNG. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at-risk patients. J Allergy Clin Immunol Pract. 2017;5(5):1264\u201371.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"998_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13223-024-00899-3","volume":"20","author":"AK Ellis","year":"2024","unstructured":"Ellis AK, Cook V, Keith PK, Mace SR, Moote W, O\u2019Keefe A, et al. Focused allergic rhinitis practice parameter for Canada. Allergy Asthma Clin Immunol. 2024;20(1):45.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"998_CR69","first-page":"348","volume":"5","author":"CL Yang","year":"2021","unstructured":"Yang CL, Hicks EA, Mitchell P, Reisman J, Podgers D, Hayward KM, et al. Canadian Thoracic Society 2021 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can J Respir Crit Care Sleep Med. 2021;5(6):348\u201361.","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"5","key":"998_CR70","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/0091-6749(89)90097-3","volume":"83","author":"BV Kettelhut","year":"1989","unstructured":"Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol. 1989;83(5):866\u201370.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"998_CR71","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/0091-6749(93)90076-R","volume":"92","author":"BS Friedman","year":"1993","unstructured":"Friedman BS, Santiago ML, Berkebile C, Metcalfe DD. Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. J Allergy Clin Immunol. 1993;92(4):520\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"998_CR72","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/all.12159","volume":"68","author":"F Siebenhaar","year":"2013","unstructured":"Siebenhaar F, Fortsch A, Krause K, Weller K, Metz M, Magerl M, et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013;68(7):949\u201352.","journal-title":"Allergy"},{"key":"998_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13223-019-0375-9","volume":"15","author":"MN Fein","year":"2019","unstructured":"Fein MN, Fischer DA, O\u2019Keefe AW, Sussman GL. CSACI position statement: newer generation H(1)-antihistamines are safer than first-generation H(1)-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"998_CR74","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0196-0644(00)43749-2","volume":"36","author":"RY Lin","year":"2000","unstructured":"Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. 2000;36(5):462\u20138.","journal-title":"Ann Emerg Med"},{"issue":"3","key":"998_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0196-0644(05)80881-9","volume":"21","author":"JW Runge","year":"1992","unstructured":"Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell SC. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med. 1992;21(3):237\u201342.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"998_CR76","doi-asserted-by":"publisher","first-page":"769","DOI":"10.7326\/0003-4819-90-5-769","volume":"90","author":"BI Hirschowitz","year":"1979","unstructured":"Hirschowitz BI, Groarke JF. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intern Med. 1979;90(5):769\u201371.","journal-title":"Ann Intern Med"},{"issue":"4","key":"998_CR77","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jaci.2024.05.026","volume":"154","author":"DG Rayner","year":"2024","unstructured":"Rayner DG, Liu M, Chu AWL, Chu X, Guyatt GH, Oykhman P, et al. Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2024;154(4):996\u20131007.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"998_CR78","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.iac.2018.04.002","volume":"38","author":"MJ Hamilton","year":"2018","unstructured":"Hamilton MJ. Nonclonal mast cell activation syndrome: a growing body of evidence. Immunol Allergy Clin North Am. 2018;38(3):469\u201381.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"998_CR79","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","volume":"85","author":"RF Horan","year":"1990","unstructured":"Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85(5):852\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"998_CR80","unstructured":"sanofi-aventis Canada Inc. PrNALCROM\u00ae Sodium Cromoglicate Capsules [Accessed: August 24, 2025]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00064157.PDF."},{"issue":"1","key":"998_CR81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000438605","volume":"38","author":"A Baba","year":"2016","unstructured":"Baba A, Tachi M, Ejima Y, Endo Y, Toyama H, Matsubara M, et al. Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing properties. Cell Physiol Biochem. 2016;38(1):15\u201327.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"998_CR82","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000249832","volume":"166","author":"BM Czarnetzki","year":"1983","unstructured":"Czarnetzki BM. A double-blind cross-over study of the effect of ketotifen in urticaria pigmentosa. Dermatologica. 1983;166(1):44\u20137.","journal-title":"Dermatologica"},{"issue":"4","key":"998_CR83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1081-1206(10)63322-4","volume":"77","author":"AM Ditto","year":"1996","unstructured":"Ditto AM, Harris KE, Krasnick J, Miller MA, Patterson R. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol. 1996;77(4):285\u201391.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"998_CR84","unstructured":"Teva Canada Limited. PrZADITEN\u00ae Ketotifen Tablets [Accessed: August 24, 2025]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00067932.PDF."},{"issue":"4","key":"998_CR85","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000144042","volume":"147","author":"JH Butterfield","year":"2008","unstructured":"Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol. 2008;147(4):338\u201343.","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"998_CR86","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","volume":"7","author":"M Castells","year":"2019","unstructured":"Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract. 2019;7(4):1097\u2013106.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"998_CR87","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/gutjnl-2019-319300","volume":"69","author":"CC Szeto","year":"2020","unstructured":"Szeto CC, Sugano K, Wang JG, Fujimoto K, Whittle S, Modi GK, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE\/APLAR\/APSDE\/APSH\/APSN\/PoA recommendations. Gut. 2020;69(4):617\u201329.","journal-title":"Gut"},{"issue":"2","key":"998_CR88","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.iac.2015.01.004","volume":"35","author":"N Fenny","year":"2015","unstructured":"Fenny N, Grammer LC. Idiopathic anaphylaxis. Immunol Allergy Clin North Am. 2015;35(2):349\u201362.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"998_CR89","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaci.2024.11.004","volume":"155","author":"C Akin","year":"2025","unstructured":"Akin C. Omalizumab for mast cell disorders. J Allergy Clin Immunol. 2025;155(1):81\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"998_CR90","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","volume":"147","author":"MC Carter","year":"2021","unstructured":"Carter MC, Maric I, Brittain EH, Bai Y, Lumbard K, Bolan H, et al. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. J Allergy Clin Immunol. 2021;147(3):1004\u201310.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"998_CR91","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000504842","volume":"236","author":"M Distler","year":"2020","unstructured":"Distler M, Maul JT, Steiner UC, Jandus P, Kolios AGA, Murer C, et al. Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA Study). Dermatology. 2020;236(6):529\u201339.","journal-title":"Dermatology"},{"issue":"7","key":"998_CR92","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.jaip.2023.04.008","volume":"11","author":"JS McComish","year":"2023","unstructured":"McComish JS, Slade CA, Buizen L, Paul SK, Chatelier JW, Unglik G, et al. Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM). J Allergy Clin Immunol Pract. 2023;11(7):2248\u201350.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"998_CR93","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.anai.2021.06.017","volume":"127","author":"LW Kaminsky","year":"2021","unstructured":"Kaminsky LW, Aukstuolis K, Petroni DH, Al-Shaikhly T. Use of omalizumab for management of idiopathic anaphylaxis: a systematic review and retrospective case series. Ann Allergy Asthma Immunol. 2021;127(4):481\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"998_CR94","unstructured":"Novartis Pharmaceuticals Canada Inc. Pr XOLAIR\u00ae Omalizumab for Injection [Accessed: August 24, 2025]. Available from: https:\/\/www.novartis.com\/ca-en\/sites\/novartis_ca\/files\/xolair_scrip_e.pdf."},{"issue":"9","key":"998_CR95","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1111\/all.15304","volume":"77","author":"T Buttgereit","year":"2022","unstructured":"Buttgereit T, Gu S, Carneiro-Leao L, Gutsche A, Maurer M, Siebenhaar F. Idiopathic mast cell activation syndrome is more often suspected than diagnosed-a prospective real-life study. Allergy. 2022;77(9):2794\u2013802.","journal-title":"Allergy"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-00998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-025-00998-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-00998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:06:20Z","timestamp":1763737580000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-025-00998-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1186\/s13223-025-00998-9","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MP received honoraria from Novartis, Sanofi, Lundbeck and Celltrion unrelated to the present work. MP is an associate editor of Allergy, Asthma & Clinical Immunology. MP acts as a principal investigator in a study sponsored by Telios. EL declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}